Biocomposites acquired the remaining shares in Laboratorios SL and Synergie Ingénierie Médicale, gaining full control of the SYNICEM and Subiton product ranges.
SYNICEM and Subiton antibiotic bone cements are manufactured in-house using proprietary core polymer production and formulation, and are available in high and low viscosities. There are also gentamicin-loaded options to support cases with a high risk of infection.
The preformed antibiotic-loaded spacers offer an alternative to traditional intra-operative molded and handmade spacers, supporting surgeons’ revisions of the hip, knee and shoulder to preserve articular space and aid the treatment of infection. Precision engineered for consistency and structural uniformity, SYNICEM and Subiton spacers provide a high local concentration of gentamicin and provide case-by-case flexibility to save surgeons’ time during their procedures.
Michael Harris, Chief Executive Officer of Biocomposites, said: “Following our initial investment in the SYNICEM and Subiton product lines in 2022, we’ve been delighted with their market-leading performance. These products fully align with our strategic aim to lead in the innovation of products for use in cases involving bone and soft tissue infection. We look forward to leveraging Biocomposites’ extensive distribution network to expand the reach of these products and serve more patients globally.”
Biocomposites acquired the remaining shares in Laboratorios SL and Synergie Ingénierie Médicale, gaining full control of the SYNICEM and Subiton product ranges.
SYNICEM and Subiton antibiotic bone cements are manufactured in-house using proprietary core polymer production and formulation, and are available in high and low viscosities. There...
Biocomposites acquired the remaining shares in Laboratorios SL and Synergie Ingénierie Médicale, gaining full control of the SYNICEM and Subiton product ranges.
SYNICEM and Subiton antibiotic bone cements are manufactured in-house using proprietary core polymer production and formulation, and are available in high and low viscosities. There are also gentamicin-loaded options to support cases with a high risk of infection.
The preformed antibiotic-loaded spacers offer an alternative to traditional intra-operative molded and handmade spacers, supporting surgeons’ revisions of the hip, knee and shoulder to preserve articular space and aid the treatment of infection. Precision engineered for consistency and structural uniformity, SYNICEM and Subiton spacers provide a high local concentration of gentamicin and provide case-by-case flexibility to save surgeons’ time during their procedures.
Michael Harris, Chief Executive Officer of Biocomposites, said: “Following our initial investment in the SYNICEM and Subiton product lines in 2022, we’ve been delighted with their market-leading performance. These products fully align with our strategic aim to lead in the innovation of products for use in cases involving bone and soft tissue infection. We look forward to leveraging Biocomposites’ extensive distribution network to expand the reach of these products and serve more patients globally.”
Copy to clipboard 
